Laparoscopic training course for trainee surgeons held in Bradford
Bradford Teaching Hospitals NHS Foundation Trust has hosted its first Royal College of Surgeons' (RCS) Intermediate Laparoscopic Skills course.
The trust is the only centre outside the London-based RCS that is accredited to run the course, and hopes to offer it bi-annually going forward.
Course director, Ahmed Elshaer, said: "This prestigious course, typically held in London, is one of the most valuable training programs offered by the RCS both nationally and internationally.
"Successfully delivering this course in Bradford for the first time marks a significant achievement, establishing the trust as a recognised regional and national centre for this esteemed course and for laparoscopic training.
"The course is designed to equip trainee surgeons, and speciality and associate specialist doctors, with essential and advanced laparoscopic skills required for their training progression.
"It provided hands-on experience in laparoscopic suturing and in laparoscopic procedures, including hernia repair, fundoplication, and bowel anastomosis, alongside structured assessment and constructive feedback to refine surgical techniques."
Tracey Harrison, the trust's simulation training lead from Education Services, added that the successful launch was "testament to the dedication and support of the trust's Simulation Centre team," which is based in Field House, Bradford Royal Infirmary.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a 'Buy' rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in the pharmaceutical sector. The company has just announced plans to present three new abstracts underscoring the impact of FILSPARI (sparsentan) in rare kidney disease at the International Podocyte Conference, taking place in Hamburg, Germany. The findings of FILSPARI, showcasing advanced reductions in urinary BAFF and sC5b9, along with dips in the proinflammatory and profibrotic biomarkers, signal a step forward in the treatment of IgAN. A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule. With net sales of FILSPARI increasing 182% year-over-year and the successful approval of FILSPARI in Europe and the UK, analysts have little doubt about the company's potential. Since the major revenue contribution comes from FILSPARI, the rising popularity and increasing adoption among nephrologists mean that Travere Therapeutics, Inc. (NASDAQ:TVTX) can continue to leverage a product that is quite differentiated. Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company incorporated in 2008. This California-based giant recognizes, develops, and commercializes therapies for people suffering from rare kidney and metabolic diseases in the United States. While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
41 minutes ago
- Yahoo
TELO Rises on Promising Telomir-1 Preclinical Results
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson's disease. In a zebrafish model mimicking Wilson's disease, the drug showed substantial dose-dependent improvements, including a decrease in tremors, a normal swimming behavior, and a 50% reduction in copper accumulation in liver tissue. It also led to better liver and kidney histopathology while restoring key biomarkers. As Dr. Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), mentioned, 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease.' A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. With a market capitalization of $59.079 million, the company is also positioning its drug through IND-enabling studies, with plans to submit its first IND for a rare disease by the year's end, followed by human trials in the first half of the next year. Analysts have set a price target of $15.50 for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), implying an upside of a whopping 688%. These well-structured plans highlight the company's position to lead the global market in the years ahead. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biopharmaceutical company that emphasizes the reversal of oxidative stress, cellular protection, and regulatory mechanisms. Incorporated in 2021, this Florida-based company is designing and developing products to address the causes of rare diseases. While we acknowledge the potential of TELO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
an hour ago
- Entrepreneur
Entrepreneur UK's London 100: Numan
Numan is one of the UK's fastest-growing digital healthcare companies, redefining how patients approach their health through personalised, technology-driven solutions Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. Industry: Healthtech Numan is one of the UK's fastest-growing digital healthcare companies, redefining how patients approach their health through personalised, technology-driven solutions. The company was founded in 2018 by Sokratis Papafloratos, an experienced entrepreneur with a track record of building and backing successful tech businesses. Numan began as a men's health startup focused on treating erectile dysfunction. In just six years, it has evolved into a full-scale digital healthcare provider, supporting over 500,000 patients through over 150 London-based staff with treatments for conditions like obesity, hair loss, and sexual health. The company generated £30m in revenue in 2023 and more than doubled that figure in 2024 – which was largely driven by the launch of their weight loss management service. The company recently launched its AI-powered Health Assistant, to support their holistic weight loss programme that includes GLP-1 prescribing. This proprietary tool is designed to provide real-time, personalised health guidance while ensuring rigorous safety and clinical oversight. With its rapid growth, technological advancements, and unwavering focus on safety and innovation, Numan is one of the most exciting and impactful London-based startups – deserving a place in the Entrepreneur UK London100 list as it continues to shape the future of digital health.
